Therefore, HOXA11-A13 positiveness, which can be identified either by gene expression or cytogenetic analysis of translocation and fusion events identified in this study, may serve as a biomarker for identification of T-ALL patients with poor prognosis. This evidence concerns the gene HOXA11 and acute lymphoblastic leukemia.